• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Dihydrocucurbitacin B Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5760312

Dihydrocucurbitacin B has anti-cancer activity, it reduces cell proliferation due to a decrease in the expression of cyclins, mainly cyclin-B1 and disruption of the actin cytoskeleton, arresting B16F10 cells in G2/M phase. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Dihydrocucurbitacin B, Inhibitor
Full Product Name
Dihydrocucurbitacin B
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
560.7
Solubility
<1mg/ml refers to the product slightly soluble or insoluble
Formula
C32H48O8
SMILES
[H][C@@]12C[C@H](O)C(=O)C(C)(C)C1=CC[C@@]1([H])[C@]3(C)C[C@@H](O)[C@H]([C@@](C)(O)C(=O)CCC(C)(C)OC(C)=O)[C@@]3(C)CC(=O)[C@@]21C
CAS Number
13201-14-4
Target & IC50
IL Receptor
TNF-alpha
COX
In Vitro
The structural changes that were performed include the removal, modification or permutation of functional groups in rings A and B as well as in the side chain. All new semisynthetic compounds, as well as 1 and 2, were tested in vitro for their cytotoxic effects on non-small-cell lung cancer cells (A549 cells). Some of these compound displayed potent to moderate activity against A549 tumor cells, especially those cucurbitacin B derivatives which were modified at ring A[1]

Product References and Citations for Dihydrocucurbitacin B, inhibitor

Synthesis and cytotoxic activity evaluation of dihydrocucurbitacin B and cucurbitacin B derivatives. Bioorg Med Chem. 2012 May 1;20(9):3016-30.
Synthesis and cytotoxic activity evaluation of dihydrocucurbitacin B and cucurbitacin B derivatives. Bioorg Med Chem. 2012 May 1;20(9):3016-30.
Evaluation of the antitumoral effect of dihydrocucurbitacin-B in both in vitro and in vivo models.Cancer Chemother Pharmacol. 2009 Aug;64(3):529-38.

Other Notes

Small volumes of Dihydrocucurbitacin B, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Dihydrocucurbitacin B purchase

MBS5760312 is an inhibitor targeting Dihydrocucurbitacin B.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000